Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

The Food and Drug Administration (FDA) is reviewing data from two clinical trials that suggest the blood pressure medication Benicar (olmesartan) may increase the risk of death from cardiovascular causes in patients with type 2 diabetes, according to an FDA safety announcement. The agency is continuing to review the data from two studies, ROADMAP and ORIENT, and is considering additional ways to asses the cardiovascular effects of Benicar.

Read the rest of this entry »

A medication primarily used to treat men with prostate cancer has been associated with a slightly increased risk for diabetes, heart attack, stroke and sudden death. The findings are preliminary and are part of an ongoing analysis of several studies by the Food and Drug Administration (FDA).

Read the rest of this entry »

A brand of the anesthetic propofol is being recalled by the Food and Drug Administration (FDA) because the injectable emulsion may contain particulate matter that could potentially impede blood flow and lead to serious health issues such as stroke, respiratory failure, kidney failure, liver failure, heart attack and/or stroke. The recall includes 85 lots of Hospira, Inc. brand Liposyn™ II 10%, Liposyn II 20%, Liposyn III 10%, Liposyn III 20%, Liposyn III 30% and 73 lots of Propofol Injectable Emulsion 1% products that begin with the lot numbers 79 and 80. The affected lots were distributed between July 2009 and October 2009.

Read the rest of this entry »